Clinical Trial: A prospective, double-cohort, multicenter clinical study evaluating the efficacy and safety of irinotecan liposome combination regimens or single-agent regimens in second-line treatment of small cell lung cancer. (China)

China, Nov. 6 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, double-cohort, multicenter clinical study evaluating the efficacy and safety of irinotecan liposome combination regimens or single-agent regimens in second-line treatment of small cell lung cancer.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136069

Registration Time: 2026/11/05

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Dalian Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=311451

Published by HT Digital Content Services with permission from Health Daily Digest....